11m
Sequana Medical announces 2024 Full Year Results and 2025 Outlook alfapump® - US FDA approval of alfapump® for the treatment of recurrent or refractory ascites due to liver cirrhosis; US commercial ...
On a sunny morning in west London, a group of around 30 protesters had gathered outside a gleaming Tesla car dealership next ...
Sequana Medical announces 2024 Full Year Results and 2025 Outlook <li /> alfapump® – US FDA approval of alf ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback